TY - JOUR T1 - Highlights from this issue JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 1 LP - 1 DO - 10.1136/bjophthalmol-2016-309597 VL - 100 IS - 10 AU - Keith Barton AU - James Chodosh AU - Jost Jonas Y1 - 2016/10/01 UR - http://bjo.bmj.com/content/100/10/1.abstract N2 - Shah et al (see page 1332)For cystoid macular edema secondary to a retinal vein occlusion, specialists would be more likely to choose bevacizumab, and would be less likely to choose aflibercept than if they were choosing the drug to treat their own disease.Rishi et al (see page 1337)Combination Photodynamic therapy and intravitreal anti-VEGF (Ranibizumab/Bevacizumab) is associated with better outcomes in eyes with myopic CNV as compared to monotherapy with PDT or anti-VEGF.Prünte et al (see page 1341)Switching from a pro re nata (PRN) to treat and extend regimen of ranibizumab in patients with nAMD resulted in significant improvements in functional and anatomical measures whilst reducing the frequency of hospital visits.Shah et al (see page 1346)Visual acuity measurement with a high-pass filtered letter chart was observed to be more sensitive to functional loss than conventional charts in age-related macular degeneration.Finger … ER -